Previous 10 | Next 10 |
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company’s executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from f...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday Moving stocks this morning are offerings, bankruptc...
The European Commission (EC) granted conditional marketing authorization to ADC Therapeutics ( NYSE: ADCT ) and Swedish Orphan Biovitrum's (Sobi) Zynlonta (loncastuximab tesirine) to treat to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the EU. The EC...
Approval triggers $50 million milestone payment to ADC Therapeutics ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi ® ) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA ® (loncas...
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company’s executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunitie...
FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS PR Newswire – Freenome's comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy ...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies agains...
ADC Therapeutics SA (ADCT) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Joe Camardo - Chief Medical Officer Jenn Creel - CFO Conference Call Participants Grego...
ADC Therapeutics press release ( NYSE: ADCT ): Q3 Non-GAAP EPS of $0.13. Revenue of $76.32M (+480.4% Y/Y). For further details see: ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022) Cash runway expected into early 2025 Company to host conference call today at 8:30 a.m. EST ADC Therapeutics SA (NYSE: ADCT) t...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...